While research on the potential of cannabis and its therapeutic properties is beginning to increase, not all countries are making the same cannabis-based drugs available. The marketing of these products depends on each country, which decides whether or not they are useful. Here is an exhaustive list.
Sativex is an oral spray from the plant’s natural extracts: it contains THC and CBD. It is a cure for neuropathic pain and spasticity related to multiple sclerosis. It can also be useful as a treatment for cancer-related pain.
The drug developed and patented by GW Pharmaceuticals in the 2000s, then marketed by Bayer and Almirall Laboratories and first launched in the United Kingdom on June 21, 2010.
Epidiolex is in the form of oil and is 98% CBD. It proves effectiveness in the treatment of severe epilepsy such as Dravet syndrome and Lennox-Gastaut. Patients who use it have reported much less frequent seizures and the drug, alike CBD oil, has been the subject of many claims from patients who do not have access to the product.
It was designed by GW Pharmaceuticals and recently approved by the FDA.
It treats nausea and vomiting in patients undergoing chemotherapy, to stimulate the appetite of AIDS patients and as an analgesic to relieve neuropathic pain in cases of multiple sclerosis.
It’s allowable in the United States, Canada, South Africa, Australia, and New Zealand. It is also allowable in most Western European countries.
Nabilone / Cesamet
Nabinole is composed of synthetic cannabinoids similar to THC. It is useful to treat nausea and vomiting due to chemotherapy.
Nabilone, was developed by Valeant Pharmaceuticals International and approved by the US Food and Drug Administration (FDA) in 1985 . It is also authorized in the United Kingdom, Australia, Canada and Mexico, and Western Europe under certain conditions.
Dexanabinol composed of non-psychotropic synthetic cannabinoids, therefore not analogous to THC, which are not present directly in the plant in the same form but act on the same receptors.
It is a neuroprotective agent to recover memory capacities and other brain functions after traumatic brain injuries. Also ,it qualifies as a potential treatment for cancer.
It is still in clinical trials and is not yet authorized anywhere. Just like CT-3 (ajulemic acid) designed by Indevus Pharmaceuticals, Cannabinor and HU 308 designed by Pharmos and HU 311 designed as an anti-cancer treatment by Cayman Chemical.
The case of Dutch Bedrocan is somewhat different since this Dutch laboratory sells cannabis flowers directly to pharmacies as a drug. It is a treatment for the variety of symptoms above. It markets 4 varieties of cannabis:
- Bedrocan: THC 22% | CBD <1.0% | Sativa
- Bedrobinol: THC 13.5% | CBD <1.0% | Sativa
- Bediol: THC 6.3% | CBD 8% | Sativa
- Bedica: THC 14% | CBD <1.0 | Indica
- Bedrolite: THC <1.0% | CBD 9% | Sativa